Aug 3, 2026
Bryan Johnson, the US tech entrepreneur known for his extreme longevity experiments, publicly expressed doubts about his life mission in a social media post, suggesting he may have taken his anti-aging efforts too far.
Scientists at Kyushu University in Japan have identified a sulfur-based compound called LASSS that protects and enhances a key muscle-repair protein called HGF, potentially offering a way to combat the muscle deterioration that occurs with aging. The compound appears to shield the protein from age-related chemical damage and more than double its strength.
The release of the 2025-2030 Dietary Guidelines for Americans has triggered scientific debate, with experts questioning whether current protein intake recommendations are sufficient for healthy aging and whether guidelines adequately address the needs of middle-aged and older adults.
Tech entrepreneur and anti-aging advocate Bryan Johnson announced he has created what he describes as a 'newborn' version of himself using stem cells, with the goal of growing replacement organs after being diagnosed with autoimmune gastritis. The controversial experiment represents his latest effort in his 'Don't Die' longevity campaign.
Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.
Tech entrepreneur Bryan Johnson, who spends $2 million annually on anti-aging treatments in his quest to 'defeat death,' revealed he has been diagnosed with autoimmune gastritis, an incurable condition causing his stomach to 'eat itself.'
The first participant has been treated in a groundbreaking clinical trial testing cellular reprogramming technology designed to rejuvenate aging cells. This marks the first time such reverse-aging therapy has been administered to a human.
Longevity-focused biotech startup NewLimit announced a $435 million Series C funding round as it prepares to launch its first clinical trial of a liver medicine, marking one of the largest recent raises in the longevity space.
Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, announced it has raised additional funding at a $1.8 billion valuation, marking significant investor confidence in the anti-aging research space.
Frequent, long, or early-day naps in older adults are linked to higher mortality risk and may signal underlying conditions like cardiovascular disease, neurodegeneration, or sleep disorders, suggesting daytime sleep patterns could serve as an early warning sign of declining health.
Research team from University of Colorado Boulder, CU Anschutz, and Colorado State University developed new therapies that prompt aging or damaged joints to regenerate, potentially reversing osteoarthritis in a matter of weeks.
An experimental drug designed to silence a gene strongly linked to Parkinson's disease showed encouraging effects in reducing the target protein by up to 60% in a first-in-human clinical trial published in Nature Medicine.
Research from the University of Oulu suggests that large variations in bedtime during midlife may double the risk of cardiovascular events, highlighting the importance of consistent sleep schedules for heart health.
Scientists at the Buck Institute for Research on Aging demonstrated that an orally administered small molecule, N-propargylglycine (N-PPG), can completely prevent the formation of calcium oxalate kidney stones in preclinical studies.